Drugs / Suvemcitug
Suvemcitug
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03763123 | Apr 2018 → Dec 2019 | ovarian cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02453464 | Aug 2015 → Dec 2016 | colorectal cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT01847118 | Apr 2013 → Nov 2015 | cancer, metastatic neoplasm | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07810114 | Aug 2026 → Dec 2027 expected | rectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05148195 | Dec 2021 → Jul 2023 | neoplasm | Jiangsu Simcere Pharmaceutical Co., Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT07361003 | Nov 2025 → Jan 2028 expected | colorectal cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04908787 | Jun 2021 → Dec 2023 | ovarian cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | Met primary |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-01-16 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results Phase III clinical trial (SCORES) data of Suvemcitug published in Nature Cancer simcere.com ↗
The study confirmed that Suvemcitug, in combination with chemotherapy, significantly extends both progression-free survival (PFS) and overall survival (OS) in patients with platinum-resistant ovarian cancer. |
| 2025-12-16 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory Simcere Zaiming Announces Inclusion of Enzeshu® (Suvemcitug for Injection) in China’s 2025 National Medical Insurance Drug List simcere.com ↗
December 7, 2025 — Simcere Zaiming, an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd. (2096.HK), today announced that its Class 1 innovative biological drug, Enzeshu® (Suvemcitug for Injection), has been officially included in China’s National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List. |
| 2024-06-04 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results The latest data from the registrational phase 3 clinical study of suvemcitug for platinum-resistant ovarian cancer has been presented as an LBA oral presentation at 2024 ASCO simcere.com ↗
On June 2, 2024, Simcere Zaiming, a leading oncology company and subsidiary of Simcere Pharmaceutical Group Ltd., announced the presentation of the latest data from the registrational phase 3 clinical study of suvemcitug for the treatment of platinum-resistant ovarian cancer. |
| 2024-03-20 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory New Drug Application Of Suvemcitug For Injection Has Been Accepted By the China National Medical Products Administration simcere.com ↗ |
| 2024-01-05 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results Suvemcitug met primary endpoint in Phase 3 Clinical Trial in China simcere.com ↗
The SCORES Study has met the primary endpoint of PFS assessed by the Blinded Independent Review Committee (BIRC) according to the RECIST 1.1 criteria. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-01-16 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase III clinical trial (SCORES) data of Suvemcitug published in Nature Cancer simcere.com ↗ |
| 2025-12-16 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere Zaiming Announces Inclusion of Enzeshu® (Suvemcitug for Injection) in China’s 2025 National Medical Insurance Drug List simcere.com ↗ |
| 2024-06-04 | Jiangsu Simcere Pharmaceutical Co., Ltd. | The latest data from the registrational phase 3 clinical study of suvemcitug for platinum-resistant ovarian cancer has been presented as an LBA oral presentation at 2024 ASCO simcere.com ↗ |
| 2024-03-20 | Jiangsu Simcere Pharmaceutical Co., Ltd. | New Drug Application Of Suvemcitug For Injection Has Been Accepted By the China National Medical Products Administration simcere.com ↗ |
| 2024-01-05 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Suvemcitug met primary endpoint in Phase 3 Clinical Trial in China simcere.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Suvemcitug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07810114 ↗ |
| Known as | APX 003 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315039 ↗ |
| Known as | BD0801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05148195 ↗ |
| Known as | Sevacizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03763123 ↗ |
| Action | Inhibit | “humanized anti-VEGF monoclonal antibody (Sevacizumab)” NCT01847118 ↗ |
| Modality | Monoclonal antibody | “humanized anti-VEGF monoclonal antibody (Sevacizumab)” NCT01847118 ↗ |